Spot early sits at the center of this dementia and brain health question.

Ophthalmologists are being trained to spot early dementia because changes in vision and retinal blood vessel structure can appear 10 to 12 years before a formal Alzheimer’s diagnosis—decades before the memory loss and cognitive decline that typically trigger a dementia workup. When a patient comes in for what they think is a routine eye exam, their retinas may already be revealing telltale signs of neurological damage that standard brain imaging would miss. This emerging capability is reshaping the role of eye doctors from focusing solely on vision correction to serving as an early warning system for one of the most devastating diseases affecting older adults.

The training represents a fundamental shift in how we might catch dementia in its earliest, most treatable stages. Rather than waiting for someone to forget appointments or struggle with familiar tasks, ophthalmologists can now identify subtle changes in retinal blood vessels, nerve fiber layer thickness, and visual processing ability that correlate with Alzheimer’s disease years before symptoms surface. A major breakthrough came in February 2026 when UC Davis launched a virtual reality eye exam program designed by neuro-ophthalmologist Yin Allison Liu specifically to identify neurological conditions including Alzheimer’s before symptoms appear. This article explores why ophthalmologists are being trained for this expanded role, how eye exams can now detect early dementia, what the science shows about retinal imaging as a biomarker, and what this means for someone over 65 scheduling their next eye appointment.

How Vision Changes Become the First Red Flag for Dementia
The Science Behind Retinal Imaging and Alzheimer’s Detection
Training Ophthalmologists to See Beyond the Surface
What This Means for Older Adults at the Eye Doctor’s Office
Limitations and Questions About Early Dementia Screening via Eye Exams
The Technologies Making Early Detection Practical
The Future of Eyes as a Window into Brain Health
Conclusion

How Vision Changes Become the First Red Flag for Dementia

The connection between eyes and dementia wasn’t obvious at first. Over the past decade, researchers have documented something striking: people who develop Alzheimer’s show measurable changes in vision—contrast sensitivity, visual attention, and even face recognition ability—that appear surprisingly early. A longitudinal study tracking 8,623 participants ages 48 to 92 found that 533 developed dementia during follow-up periods extending as long as 14.8 years. Among those who went on to develop cognitive decline, changes in vision sensitivity were present years earlier, proving to be as sensitive as traditional neurocognitive diagnostic tests at detecting the disease’s approach. What makes this significant is the timeline.

A person might notice they’re struggling to see objects against a similar-colored background (contrast sensitivity) or having trouble recognizing a familiar face in a crowd long before they forget their grandchild’s name. These aren’t subtle quirks—they’re measurable, reproducible changes in how the eye processes visual information. The brain and the eye are connected through the optic nerve; when Alzheimer’s pathology begins damaging neurons in the brain, it simultaneously damages neurons in the retina. The retina is essentially an extension of the central nervous system, making it a window into what’s happening deeper in the brain. The practical implication is sobering: millions of people walking around with undiagnosed early Alzheimer’s have already shown these visual signs to an ophthalmologist, who had no training to recognize them as anything other than normal aging.

How Vision Changes Become the First Red Flag for Dementia

The Science Behind Retinal Imaging and Alzheimer’s Detection

Modern retinal imaging technology has made it possible to detect these changes with precision. The Eye-AD deep learning framework—an AI system trained to recognize Alzheimer’s patterns in retinal images—demonstrates remarkably high accuracy. For early-onset Alzheimer’s disease, the system achieved an AUC (Area Under the Curve, a measure of diagnostic accuracy) of 0.9355 in internal testing and 0.9007 when tested on external data. For mild cognitive impairment, the internal AUC was 0.8630 and external was 0.8037. These aren’t perfect, but they’re in the range where clinicians take results seriously and use them to inform next steps. The technologies enabling this detection are already part of many ophthalmology practices.

Optical Coherence Tomography (OCT) images the retina in high resolution and can detect peripapillary retinal nerve fiber layer thinning—a hallmark of Alzheimer’s. OCT Angiography (OCTA) goes further, measuring the foveal avascular zone (the space in the center of the retina where blood vessels form a ring) and mapping out changes in the retinal microvasculature. Fundus photography analyzes the fractal dimension of arterioles and venules—essentially, how the branching patterns of blood vessels change. Eye-tracking technology during cognitive testing detects visuospatial processing impairment that shows up even in early Alzheimer’s stages. However, there’s an important caveat: retinal changes correlate with Alzheimer’s risk, but they don’t definitively diagnose the disease. A person with abnormal retinal imaging might develop cognitive decline, or they might have the brain pathology without experiencing symptoms during their lifetime. The research is still clarifying which changes mean imminent decline and which represent harbingers that may take years to manifest as actual cognitive symptoms.

Training Ophthalmologists to See Beyond the Surface

The UC Davis virtual reality eye exam program exemplifies how ophthalmologists are being trained differently than in the past. Rather than just testing whether someone can read letters on a chart, the VR platform combines eye health assessment with cognitive and neurological screening. The program is designed to identify not only Alzheimer’s but a spectrum of neurological conditions—all during a procedure that feels like a standard, non-invasive eye exam. Yin Allison Liu, the neuro-ophthalmologist who developed the program, recognized that eyes provide a unique diagnostic opportunity.

The optic nerve, retinal blood vessels, and the visual processing regions of the brain are all accessible and measurable through the eye. Unlike a brain biopsy or even an MRI, an eye exam is something most people already have regularly. Extending that exam to include neurological screening means potentially reaching millions of people who would never volunteer for separate dementia screening. The training programs being rolled out to ophthalmologists now include recognition of specific red flags: accelerated retinal nerve fiber layer thinning, changes in blood vessel patterns, and abnormal eye-tracking results during visual tasks. It’s a skill set that didn’t exist in ophthalmology five years ago, but is becoming standard in some practices today.

Training Ophthalmologists to See Beyond the Surface

What This Means for Older Adults at the Eye Doctor’s Office

For someone over 65, the practical implication is that an eye exam may soon provide information about dementia risk that they didn’t go in expecting to receive. Currently, the American Academy of Ophthalmology recommends that seniors over 65 have eye exams every 1 to 2 years. As retinal imaging for dementia detection becomes more widespread, these routine visits could potentially identify 4 to 8 million individuals in the U.S. with dementia risk during standard optometric care. This creates both an opportunity and an ethical question. Identifying someone as high-risk for Alzheimer’s years before symptoms appear is valuable only if it leads to intervention that slows decline or improves outcomes.

Current treatments for early Alzheimer’s—monoclonal antibodies targeting amyloid, lifestyle interventions—show modest benefits, but they’re most effective when started as early as possible. If retinal imaging identifies someone at high risk, they can begin these treatments immediately rather than waiting years until cognitive changes are obvious. The alternative is knowing about the risk but having limited options, which can provoke anxiety without corresponding benefit. The comparison is instructive: detecting Alzheimer’s risk via retinal imaging is conceptually similar to finding high cholesterol on a blood test. The finding itself doesn’t diagnose disease, but it prompts preventive action. However, unlike high cholesterol, where dietary and pharmaceutical interventions have proven benefits, Alzheimer’s prevention remains partially unproven—making the decision to pursue early detection more complex.

Limitations and Questions About Early Dementia Screening via Eye Exams

One critical limitation: not everyone with Alzheimer’s pathology develops dementia. Autopsy studies have shown that roughly 30 percent of cognitively normal older adults who died had Alzheimer’s pathology in their brains. If retinal imaging identifies these individuals, they’ll worry about a disease they might never develop. This is called the “overdiagnosis” problem, and it’s a genuine concern as retinal imaging becomes more sensitive. Another limitation is disparities in access.

The technologies needed for advanced retinal imaging—high-resolution OCT, OCTA, AI-powered analysis software—are concentrated in academic medical centers and well-funded ophthalmology practices. Rural areas and underserved communities will continue relying on basic eye exams for years, meaning that the benefits of early dementia detection via retinal imaging will flow disproportionately to those with access to specialized care and the ability to pursue follow-up testing and treatment. There’s also the question of insurance coverage. Right now, retinal imaging for dementia screening is largely a research tool. Insurance companies have not agreed to reimburse ophthalmologists specifically for dementia risk assessment through eye exams, which creates a financial barrier to widespread implementation.

Limitations and Questions About Early Dementia Screening via Eye Exams

The Technologies Making Early Detection Practical

The tools that make this possible are advancing rapidly. Optical Coherence Tomography (OCT) has been in clinical use for decades, but current machines provide image quality that previous generations couldn’t achieve. The retinal nerve fiber layer can be measured to within micrometers. OCT Angiography—which adds blood flow mapping to the imaging—is now available in most larger practices and reveals vascular changes too subtle for the human eye to detect on fundus photographs alone.

A real-world example: A 68-year-old woman comes in complaining that she’s having trouble reading small print. During her OCT scan, the machine detects that her retinal nerve fiber layer thickness is in the bottom 5 percent for her age—an unusual finding in someone with her visual complaint. The retinal blood vessels also show a pattern consistent with early vascular changes associated with Alzheimer’s. Ten years ago, the ophthalmologist might have written “normal healthy retina” in her chart. Today, that same finding prompts a referral to neurology, cognitive testing, and possibly early intervention with anti-amyloid therapy.

The Future of Eyes as a Window into Brain Health

What happens next depends largely on whether retinal imaging becomes standardized in ophthalmology training and whether third-party payers decide to cover the tests. If they do, eye exams will transform from a vision-focused intervention into a comprehensive brain health assessment tool. If they don’t, early dementia detection via retinal imaging will remain confined to academic settings and specialty practices.

The field is moving toward that standardization. The American Academy of Ophthalmology and the Alzheimer’s Association are collaborating on educational initiatives. Research showing that retinal changes precede cognitive symptoms by a decade is pushing the clinical consensus toward screening. Within five to ten years, it’s plausible that an eye exam for someone over 65 will routinely include retinal imaging for dementia risk, just as blood pressure monitoring is now standard during an eye visit.

Conclusion

Ophthalmologists are being trained to spot early dementia because the eye is literally a window into the brain, and modern imaging technology can detect pathological changes 10 to 12 years before cognitive symptoms appear. Technologies like OCT, OCTA, and AI-powered image analysis make these changes visible and measurable. Major research institutions including UC Davis, Duke, and the institutions represented in the Eye-AD framework have demonstrated that retinal imaging can identify Alzheimer’s risk with high accuracy.

For someone concerned about dementia risk, or simply scheduling their next eye exam, the practical step is straightforward: discuss your family history of cognitive decline with your eye doctor and ask whether they perform advanced retinal imaging for neurological assessment. If they do, it’s worth including in your standard care. If they don’t, you might ask when they expect to offer it. The field is shifting, and eye exams are becoming a tool for detecting the early stages of dementia when intervention is most likely to help.